Latest news with #Agilent
Time of India
3 days ago
- Business
- Time of India
Agilent opens new biopharma centre in Hyd
Hyderabad: US-based analytical and clinical laboratory technologies player Agilent Technologies Inc has opened its new biopharma experience centre in Hyderabad. The facility will offer advanced laboratory technologies, expert training, and regulatory-ready workflows to expedite the development of high-quality, life-saving medicines. It will provide comprehensive solutions in chromatography, mass spectrometry, cell analysis, and lab informatics, enabling companies to simulate real lab environments and develop market-ready solutions, Agilent said. The new centre will also drive collaboration between industry and academia, support faster R&D, and align with international regulatory standards. Inaugurating the new facility on Tuesday, Telangana IT and industries minister Duddila Sridhar Babu said the centre will bolster Hyderabad's position as a leader in life sciences and healthcare innovation. He said Hyderabad's robust life sciences ecosystem contributes to nearly one-third of India's pharmaceutical production and 40% of bulk drug exports. You Can Also Check: Hyderabad AQI | Weather in Hyderabad | Bank Holidays in Hyderabad | Public Holidays in Hyderabad Agilent Technologies CEO Padraig McDonnell said: "India is a strategic growth market for Agilent, and Hyderabad is at the forefront of biopharma innovation. This new centre reflects our commitment to delivering integrated solutions that help bring life-changing therapies to market faster and more efficiently. It also reinforces our support for the 'Make-in-India' initiative by empowering local innovation, nurturing talent, and enabling scalable, affordable, and sustainable solutions. " He said the investment is part of the company's broader strategy to expand its footprint in India and position it as a strategic hub in its global innovation roadmap.
Hans India
02-08-2025
- Health
- Hans India
Agilent and Tata Institute of Fundamental Research, Hyderabad collaborate to advance scientific frontiers in health and metabolism research
In a significant step toward strengthening India's efforts in nutrition and metabolism research, Agilent Technologies and the Tata Institute of Fundamental Research (TIFR), Hyderabad have announced a strategic collaboration to support ARUMDA (Advanced Research Unit on Metabolism, Development, and Aging). This partnership brings together Agilent's global expertise in analytical science with TIFR's research endeavors to address the growing burden of non-communicable diseases (NCDs) and malnutrition in the country. A key outcome of this collaboration is the launch of the Agilent–TIFR Center of Translational Research in Hyderabad. The center will play a pivotal role in supporting the Advanced Research Unit on Metabolism, Development & Aging (ARUMDA)—one of India's most ambitious government-supported initiatives in human health. ARUMDA is focused on bridging fundamental biology with clinical insights to drive data-driven discovery and inform public health strategies. Agilent's role centers on enabling this vision through high-performance analytical solutions that support impactful translational research. This collaboration reflects a shared commitment to advancing science that is rigorous, relevant, and aligned with national health priorities. It is designed to empower researchers with the tools and workflows needed to explore complex biological systems, generate population-specific insights, and translate them into meaningful interventions. Agilent is contributing to advanced analytical capabilities that support key areas such as molecular profiling, metabolomics, trace element analysis, and cellular bioenergetics. These integrated solutions help researchers navigate the intricacies of human biology and uncover insights that can guide future interventions—particularly in the context of large-scale, population-based studies. This approach reinforces the collaboration's focus on enabling science that is both data-driven and impactful. 'Our partnership with TIFR reflects Agilent's commitment to enabling transformative science through technology, collaboration, and shared purpose,' said Nandakumar Kalathil, Country General Manager, Agilent Technologies India. 'We are proud to support a project of this scale and ambition—one that aligns with national priorities and has the potential to deliver real-world health impact.' Prof. M. Krishnamurthy, Centre Director, TIFR Hyderabad, added, 'This partnership represents a meaningful step forward in our efforts to translate fundamental research into real-world solutions. The Agilent–TIFR Center of Translational Research will enhance our scientific capabilities and contribute to national efforts in addressing the growing burden of lifestyle-related diseases.' The collaboration also supports the development of a new analytical facility in Hyderabad, established in partnership with the National Analytical Facility for Research in Nutrition and Metabolism, under the ARUMDA umbrella. Aligned with the National Nutrition Mission, the facility is expected to play a critical role in advancing India's research capabilities in metabolic health and nutrition science. By combining deep scientific inquiry with advanced analytical technologies, Agilent and TIFR are helping shape a future where research is more connected, more interdisciplinary, and more responsive to the evolving health needs of society. This partnership also reflects Agilent's long-standing commitment to supporting India's scientific ecosystem—enabling innovation that spans academia, public health, and industry.
Hans India
31-07-2025
- Business
- Hans India
Agilent Supports India's Global Biopharma Ambitions with State-of-the-Art Experience Center in Hyderabad
Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical markets, today announced the inauguration of its new Biopharma Experience Center in Hyderabad, Telangana. The facility marks a significant investment in India's rapidly growing life sciences ecosystem and reflects Agilent's long-term commitment to advancing biopharmaceutical innovation both locally and globally. The center was inaugurated by Shri Duddila Sridhar Babu, Hon'ble Minister for Information Technology, Electronics, Communications, and Industries, Government of Telangana, in the presence of Agilent President and CEO Padraig McDonnell, along with senior leaders from India's pharmaceutical and biopharma sectors. The new Agilent Biopharma Experience Center in Hyderabad presents a major opportunity to accelerate the city's leadership in life sciences and healthcare innovation. Designed to support the full drug development journey, the center brings together advanced lab technologies, expert training, and regulatory-ready workflows to help researchers, scientists, and companies develop high-quality, life-saving medicines faster and more efficiently. It offers end-to-end solutions across key modalities such as chromatography, mass spectrometry, cell analysis, and lab informatics, allowing companies to simulate real lab environments, test for quality and compliance, and co-create market-ready solutions tailored to both Indian and global needs. For Hyderabad's vibrant ecosystem of startups, academic institutions, and skilled professionals, the center unlocks direct access to global expertise, cutting-edge instrumentation, and real-world application environments. It supports faster R&D, hands-on training aligned with international regulatory standards, and stronger collaboration between industry and academia. By addressing critical challenges in biosimilars, biologics, and precision medicine, the facility strengthens Hyderabad's position as a trusted global hub for next-generation drug development, and a key contributor to India's biopharma growth story. 'India is a strategic growth market for Agilent, and Hyderabad is at the forefront of biopharma innovation,' said Padraig McDonnell, CEO, Agilent Technologies. 'Our future will be defined by continued innovation and a relentless focus on our customers. This new center reflects our commitment to delivering integrated solutions that help bring life-changing therapies to market faster and more efficiently. It also reinforces our support for the 'Make-in-India' initiative by empowering local innovation, nurturing talent, and enabling scalable, affordable, and sustainable solutions.' Located in the heart of India's life sciences capital, the center is designed to address critical gaps in analytical capabilities and regulatory readiness for biopharma companies. It will serve as a hub for innovation and collaboration, supporting the development of biologics, biosimilars, and precision medicine. Shri Duddila Sridhar Babu, Hon'ble Minister for Information Technology, Electronics, Communications, and Industries, Government of Telangana said, 'Hyderabad has emerged as a complete healthcare and life sciences ecosystem—from drug discovery and clinical trials to world-class hospitals and affordable, high-quality patient care. We are proud to host eight of the top ten global pharma companies, five of India's leading healthcare chains, and over 230 USFDA-approved manufacturing facilities. Contributing nearly one-third of India's pharmaceutical production and 40% of bulk drug exports, Telangana is making a strong impact both nationally and globally. With a strong talent base and a clear focus on innovation, we are building a future-ready healthcare system. The launch of the Agilent Biopharma Experience Center is a significant milestone in strengthening Telangana's position as a global leader in life sciences, and a valuable addition to our expanding innovation-driven ecosystem.' Hyderabad offers one of the most mature and future-focused life sciences ecosystems in India, combining deep industry expertise, strong R&D capabilities, and a supportive policy environment. With its legacy in generics and a growing focus on advanced therapies, the city is well-positioned for the next phase of healthcare innovation. The launch of the Agilent Biopharma Experience Center builds on this foundation, introducing advanced analytical and regulatory capabilities that support both local innovation and global delivery. This capital investment is part of Agilent's broader three-to-five-year India growth strategy, which includes expanding its footprint, deepening customer partnerships, and positioning India as a strategic hub in Agilent's global innovation and profitability roadmap. The India Solution Center in Manesar, launched earlier this year, further reflects this ongoing commitment—contributing to Agilent's efforts to enhance its presence and capabilities in one of its fastest-growing, high-priority markets globally. 'Agilent is already working closely with many of India's leading biopharma companies,' added McDonnell. 'With this center, we aim to strengthen those relationships and co-create solutions that meet the evolving needs of the Indian and global markets.' This milestone marks a new chapter in Agilent's journey with India—deepening collaboration, accelerating innovation, and contributing to a healthier, more sustainable future.
New Indian Express
30-07-2025
- Business
- New Indian Express
Agilent opens its Indian biopharma capability center in Hyderabad
CHENNAI: Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical markets, has inaugurated its new Biopharma Capability Center in Hyderabad. The facility represents a significant investment in India's expanding life sciences ecosystem and aligns with the U.S.-based company's broader three-to-five-year growth strategy for the country. The center was inaugurated by Telangana's Minister for Information Technology, Electronics, Communications, and Industries, Duddila Sridhar Babu, in the presence of Agilent's global CEO Padraig McDonnell. Designed to support the entire drug development process, the center features advanced laboratory technologies, expert training, and regulatory-ready workflows to help researchers, scientists, and companies develop high-quality, life-saving medicines. It will serve as a hub for innovation and collaboration, focusing on the development of biologics, biosimilars, and precision medicine. The facility offers end-to-end solutions across key modalities such as chromatography, mass spectrometry, cell analysis, and lab informatics. These capabilities allow companies to simulate real laboratory environments, test for quality and compliance, and co-create solutions tailored to both Indian and global markets. For Hyderabad's biopharma startups, academic institutions, and skilled professionals, the center provides access to global expertise, cutting-edge instrumentation, and real-world application environments. It supports accelerated R&D, hands-on training aligned with international regulatory standards, and fosters stronger industry-academia collaboration. 'India is a strategic growth market for Agilent, and Hyderabad is at the forefront of biopharma innovation,' said Padraig McDonnell, CEO of Agilent Technologies. 'Our future will be shaped by continued innovation and a relentless focus on our customers.' 'This new experience center reinforces our support for the 'Make-in-India' initiative by empowering local innovation, nurturing talent, and enabling scalable, affordable, and sustainable solutions,' McDonnell added. Commenting on the launch, Minister Sridhar Babu said, 'With a strong talent base and a clear focus on innovation, we are building a future-ready healthcare system. The Agilent Biopharma Experience Center is a significant milestone that strengthens Telangana's position as a global life sciences leader and adds value to our growing innovation-driven ecosystem.' Telangana currently accounts for nearly one-third of India's pharmaceutical production and 40% of bulk drug exports. Hyderabad boasts one of the most mature and future-focused life sciences ecosystems in India, with deep industry expertise, strong R&D capabilities, and a conducive policy environment. Building on the city's legacy in generics and increasing emphasis on advanced therapies, the new center adds cutting-edge analytical and regulatory capabilities that support local innovation and global delivery. Earlier this year, Agilent also launched its India Solution Center in Manesar. With this expansion, the company is deepening customer partnerships and positioning India as a strategic hub in its global innovation and growth roadmap. 'Agilent is already working closely with many of India's leading biopharma companies,' McDonnell said. 'With this center, we aim to strengthen those relationships and co-create solutions that address the evolving needs of both Indian and global markets.'
The Hindu
29-07-2025
- Business
- The Hindu
Agilent Tech opens Biopharma Experience Centre in Hyderabad
NYSE-listed global leader in Life Sciences, diagnostics and applied chemical markets Agilent Technologies has established a Biopharma Experience Centre in Hyderabad to support the drug development journey of its customers. End-to-end solutions across key modalities such as chromatography, mass spectrometry, cell analysis and lab informatics that will allow its customers to simulate real lab environments are available. The companies can test for quality and compliance and co-create market-ready solutions, Industries and IT Minister Babu's office said after he inaugurated the facility on Tuesday. Launch of the facility is a significant milestone in strengthening Telangana's position as a global leader in Life Sciences and a valuable addition to expanding innovation-driven ecosystem, the Minister said. Rounded ecosystem Hyderabad has emerged as a complete healthcare and life sciences ecosystem, from contributing to drug discovery and clinical trials to playing host to world-class hospitals and affordable, high-quality patient care. 'We are proud to host eight of the top ten global pharma companies, five of India's leading healthcare chains and over 230 U.S Food and Drug Administration (U.S FDA)-approved manufacturing facilities,' Babu said. Telangana contributes nearly one-third of India's pharmaceutical production and 40% of bulk drug exports from the country. 'With a strong talent base and a clear focus on innovation, we are building a future-ready healthcare system,' he said. Agilent's new facility is poised to serve as a hub for innovation and collaboration, supporting development of biologics, biosimilars and precision medicine, the Minister's office said. 'India is a strategic growth market for Agilent,' Agilent president and CEO Padraig McDonnell said. Serving as foundation for the new centre is Hyderabad's mature and future-focused life sciences ecosystem that thrives on deep industry expertise, strong research and development capabilities and a supportive policy environment. With its legacy in generics and a focus on advanced therapies, the city is well-positioned for the next phase of healthcare innovation. Without mentioning either the investment or hiring plans, Agilent said its capital investment in the facility is part of a broader three-to-five-year India growth strategy. The India Solution Centre in Manesar launched earlier this year further is a reflection of its commitment to enhance presence and capabilities in one of its fastest-growing, high-priority markets globally.
